Water-Only Fasting Dropped Blood Pressure by 37 Points in a Clinical Trial

Nearly one in two American adults has hypertension, yet fewer than one in five has their blood pressure under control, according to CDC data from 2021 to 2023. Drugs help, but they are rarely the whole answer, and researchers have long searched for lifestyle interventions that can move the needle in a meaningful way. A clinical trial published in the journal of the American Medical Association offers a striking, if preliminary, data point: medically supervised water-only fasting normalized blood pressure in almost 90% of the 174 hypertensive patients who completed the protocol.

Water-Only Fasting Cut Average Blood Pressure by 37/13 mm Hg

174 consecutive hypertensive patients, all with blood pressure exceeding 140/90 mm Hg, enrolled in an inpatient treatment program. By the end of the intervention, 89% had reached the clinical threshold of less than 140/90 mm Hg. The average reduction across all participants was 37/13 mm Hg, a drop large enough to shift many patients from a medicated high-risk category to a normal range. Every patient who arrived on antihypertensive medication, 6.3% of the sample, successfully discontinued use by the end of the program. The study authors concluded that medically supervised water-only fasting appears to be a safe and effective means of normalizing blood pressure, and that it may help motivate lasting changes in diet and lifestyle.

Stage 3 Hypertension Patients Saw the Steepest Reductions

The most compelling numbers came from patients with stage 3 hypertension, the most severe classification. This subgroup averaged a reduction of 60/17 mm Hg, nearly double the average for the cohort as a whole. That pattern, where the intervention delivers the largest benefit to those who need it most, is clinically significant: it suggests the protocol is not simply regressing toward the mean but producing a genuine physiological response proportional to the severity of the underlying condition. The result also implies that patients who have failed to control blood pressure through medication alone may have the most to gain from fasting-based approaches, if these findings hold up under more rigorous scrutiny.

The Protocol Combined Pre-Fasting, Water-Only Days, and Vegan Refeeding

The intervention was not simply a period of starvation. The program unfolded in three structured phases. First came a 2 to 3-day pre-fasting period during which patients ate only fruit and vegetables, shifting the gut away from calorie-dense, processed food. That preparation gave way to approximately 10 to 11 days of water-only fasting under continuous medical supervision in an inpatient setting, where clinical staff could monitor electrolytes, blood pressure, and any adverse signs. The program closed with a refeeding period of roughly 6 to 7 days that gradually reintroduced a low-fat, low-sodium, whole-food vegan diet. The careful structure matters: an observational study of 1,422 subjects who underwent supervised fasting using the Buchinger protocol found that medically monitored multi-day fasts can be conducted safely when daily clinical oversight is maintained, though that program differed in design. The inpatient setting in this trial gave clinicians the ability to intervene immediately if problems arose, which is central to why the researchers could describe the protocol as safe.

No Control Group Limits How Far These Results Can Travel

As an early clinical trial, this study has real constraints. There was no randomized control group, so it is impossible to rule out effects from the structured diet before and after the fast, the inpatient environment itself, the attention of medical staff, or simple regression to the mean for patients whose blood pressure was elevated at the time of enrollment. The cohort was also relatively small and drawn from a single clinical setting, which limits how broadly the results can be generalized. A narrative review of human trials examining prolonged water fasting flags additional concerns worth noting: extended fasting carries risks including excessive lean mass loss, metabolic acidosis, headaches, and disrupted sleep. None of those adverse events were reported as disqualifying in this study, but the review underscores that water-only fasting is not without hazard, particularly outside a closely supervised clinical environment. These findings should be treated as investigational, not as a clinical recommendation.

What a Controlled Trial Would Need to Answer

For this approach to move from promising to practice-changing, it would need to survive a randomized controlled trial with a comparator arm, ideally matched for caloric restriction, dietary quality, and clinical attention. Long-term follow-up data would be equally important: blood pressure normalized at the end of a three-week inpatient program is not the same as blood pressure controlled at six or twelve months, especially once patients return to ordinary life. The study authors suggest the protocol may help initiate health-promoting behavioral changes, and that mechanism, motivation and habit formation rather than the fast itself, could be tested independently. Whether the blood pressure reduction comes primarily from the fasting, the vegan refeeding diet, the sodium restriction, or some combination remains an open question that future trials would need to disentangle. Until that work is done, the 37/13 mm Hg average reduction is striking enough to warrant serious follow-up research, and serious caution about overstating what has been shown.

Evidence rating

INVESTIGATIONAL — 57/100

Single-arm uncontrolled clinical trial (n=174) examining water-only fasting for hypertension. Shows pre-post blood pressure change without a control group, limiting causal inference. No gut microbiome mechanism or data is presented, making this outside the domain scope.